内路植入小梁微旁路支架联合白内障手术治疗原发性开角型青光眼的前瞻性随机对照 pivotal 试验:两年结果
这项前瞻性、随机、单盲、多中心对照试验评估了 iStent inject 小梁微旁路系统联合白内障手术治疗轻中度原发性开角型青光眼(POAG)的安全性和有效性。术后 24 个月,治疗组无药物日间眼压(DIOP)较基线降低 ≥20% 的比例为 75.8%,显著高于对照组的 61.9%(P=0.005),平均降幅也更大(7.0±4.0 mmHg vs 5.4±3.7 mmHg,P<0.001)。治疗组整体安全性良好,与对照组相似。
要点
- iStent inject 联合白内障手术在 24 个月时无药物 DIOP 降幅显著优于单纯白内障手术。
- 治疗组 75.8% 患眼达到无药物 DIOP 较基线降低 ≥20%,对照组为 61.9%。
- 治疗组整体安全性良好,与对照组相似。
核心结论
- 联合白内障手术植入 iStent inject 相比单纯白内障手术,在无药物条件下获得了临床和统计学上更大的眼压降低,且两年安全性良好。
研究设计与样本
- 前瞻性、随机、单盲、同期对照、多中心临床试验。
- 纳入轻中度 POAG 且术前用药后眼压 ≤24 mmHg、未用药日间眼压 21 至 36 mmHg、需白内障手术的患眼。
- 白内障手术后将患眼按 3:1 随机分配至 iStent inject 植入组(n=387)或不植入支架的对照组(n=118),随访 2 年,每年进行降眼压药物洗脱。
主要发现
- 术前两组用药后眼压均为 17.5 mmHg,未用药 DIOP 分别为 24.8±3.3 mmHg(治疗组)和 24.5±3.1 mmHg(对照组),P=0.33。
- 24 个月时,治疗组 75.8% 患眼和对照组 61.9% 患眼无药物 DIOP 较基线降低 ≥20%(P=0.005)。
- 24 个月时,治疗组无药物 DIOP 平均降幅为 7.0±4.0 mmHg,对照组为 5.4±3.7 mmHg(P<0.001)。
- 在应答者中,23 个月时治疗组 84% 患眼和对照组 67% 患眼未使用降眼压药物。
- 24 个月时,治疗组 63.2% 患眼和对照组 50.0% 患眼无药物 DIOP ≤18 mmHg(差异 13.2%;95%CI 2.9-23.4)。
临床怎么用
- 对于合并白内障的轻中度 POAG 患者,可考虑在白内障手术中联合植入 iStent inject 以增强无药物眼压控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Evaluate the safety and effectiveness of an ab interno implanted (iStent inject) Trabecular Micro-Bypass System (Glaukos Corporation, San Clemente, CA) in combination with cataract surgery in subjects with mild to moderate primary open-angle glaucoma (POAG). DESIGN: Prospective, randomized, single-masked, concurrently controlled, multicenter clinical trial. PARTICIPANTS: Eyes with mild to moderate POAG and preoperative intraocular pressure (IOP) ≤24 mmHg on 1 to 3 medications, unmedicated diurnal IOP (DIOP) 21 to 36 mmHg, and cataract requiring surgery. METHODS: After uncomplicated cataract surgery, eyes were randomized 3:1 intraoperatively to ab interno implantation of iStent inject (Model G2-M-IS; treatment group, n = 387) or no stent implantation (control group, n = 118). Subjects were followed through 2 years postoperatively. Annual washout of ocular hypotensive medication was performed. MAIN OUTCOME MEASURES: Effectiveness end points were ≥20% reduction from baseline in month 24 unmedicated DIOP and change in unmedicated month 24 DIOP from baseline. Safety measures included best spectacle-corrected visual acuity (BSCVA), slit-lamp and fundus examinations, gonioscopy, pachymetry, specular microscopy, visual fields, complications, and adverse events. RESULTS: The groups were well balanced preoperatively, including medicated IOP (17.5 mmHg in both groups) and unmedicated DIOP (24.8±3.3 mmHg vs. 24.5±3.1 mmHg in the treatment and control groups, respectively, P = 0.33). At 24 months, 75.8% of treatment eyes versus 61.9% of control eyes experienced ≥20% reduction from baseline in unmedicated DIOP (P = 0.005), and mean reduction in unmedicated DIOP from baseline was greater in treatment eyes (7.0±4.0 mmHg) than in control eyes (5.4±3.7 mmHg; P < 0.001). Of the responders, 84% of treatment eyes and 67% of control eyes were not receiving ocular hypotensive medication at 23 months. Furthermore, 63.2% of treatment eyes versus 50.0% of control eyes had month 24 medication-free DIOP ≤18 mmHg (difference 13.2%; 95% confidence interval, 2.9-23.4). The overall safety profile of the treatment group was favorable and similar to that in the control group throughout the 2-year follow-up. CONCLUSIONS: Clinically and statistically greater reductions in IOP without medication were achieved after iStent inject implantation with cataract surgery versus cataract surgery alone, with excellent safety through 2 years.
引用
- Samuelson TW, Sarkisian SR, Lubeck DM, et al. Prospective, Randomized, Controlled Pivotal Trial of an Ab Interno Implanted Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: Two-Year Results. Ophthalmology. 2019. PMID: 30880108. doi:10.1016/j.ophtha.2019.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。